The Latest Breaking News from biotechnology

Gujarat to turn ocean into next big industry: Rs 100 crore marine biotech corridor planned in Porbandar; seaweed, algae & microbes could soon fuel new business boom

An initiative of the Gujarat State Biotechnology Mission (GSBTM), Department of Science and Technology, the proposed corridor is envisioned as an integrated ecosystem connecting marine science, biotechnology research, field cultivation, technology development, pilot-scale biomanufacturing, entrepreneurship and commercialisation, according to the Chief Minister's Office.

The Economic Times · Oct 8

Global Market: Hong Kong stocks fall as oil rises, tech and biotech shares drag

Hong Kong stocks fell as rising oil prices, weak economic data and selling in major technology and biotechnology shares weighed on sentiment. The Hang Seng declined 0.5%, while tech stocks dropped 0.9%. A weak PMI, subdued consumer demand and mixed industrial data added caution, despite optimism from China’s policy support.

The Economic Times · Oct 7

1920 Maryland factory that made WWII rations, gets new life with a $1 million oyster centre

A Maryland factory built in 1920 and later linked to the Phillips Packing Company has been transformed from a vacant site into a business and community hub. The Packing House now hosts offices, retail and event spaces, while a $1 million state project is creating an oyster-focused centre for processing,…

The Times of India · Sep 29

Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside — Should you subscribe?

Symbiotec Pharmalab's IPO saw robust investor demand, with the issue subscribed 1.85 times. The company aims to raise Rs 1,757 crore through a fresh issue and offer for sale. Its shares are currently trading at a significant grey market premium, indicating listing gain potential.

The Economic Times · Aug 25

Symbiotec Pharmalab’s Rs 1,757 crore IPO opens with GMP hinting at 41% upside. Should you bid?

Symbiotec Pharmalab IPO GMP: Symbiotec Pharmalab’s Rs 1,757 crore IPO opened August 24, with a Rs 938–988 price band and 41% grey-market premium. The issue combines fresh shares and an OFS, while proceeds will partly repay debt. Its specialised API manufacturing, regulatory approvals and biotechnology capabilities offer investors exposure to…

The Economic Times · Aug 24

IIT Delhi engineer develops fridge that runs without truck engine, cuts cooling costs by 75%

A post on X has highlighted Yotuh Energy, a company co-founded by IIT Delhi biotechnology graduate Shaivee Malik, which has developed a battery-powered refrigeration system for transport vehicles. The technology works independently of truck engines, can run for six to eight hours and is claimed to cut refrigeration costs by…

The Economic Times · Aug 23

Spider Silk Is Being Tested as Surgical Sutures, Wound Dressings, and Biomedical Protein Material

The thread that outperforms steelA dragline silk thread spun by Nephila pilipes, the giant golden orb-weaver found across South and Southeast Asia, has a tensile strength of roughly 1.3 gigapascals, stronger than high-grade steel at a fraction of the weight. That single biological fact is what has made spider silk…

Times Life · Aug 22

Horseshoe Crab Blood Powers Every Vaccine and Injection You Have Ever Been Given

The blue blood that guards every hospital on EarthHorseshoe crab blood is blue. Not metaphorically, literally blue, because it uses copper-based hemocyanin to carry oxygen instead of the iron-based hemoglobin that makes human blood red. But the colour is not why the biomedical industry harvests roughly 600,000 horseshoe crabs every…

Times Life · Aug 21

The use of AI in biotechnology is changing faster than the rules governing either technology

The recent announcement of novel, viable viruses created by artificial intelligence (AI) was celebrated as a major advance in the fight against antibiotic resistance. But it also raised urgent concerns about regulation.

The Conversation · Aug 18

Congressional Panel Says the United States Is Losing Its Lead on Rare Disease Cures

A bipartisan congressional advisory commission identified four barriers keeping rare disease therapies from patients and urged an all-of-government response.

Medical Daily · Aug 8